The mechanism by which neuroleptics induce therapeutic effects remains elusive. Early receptor binding studies demonstrated a strong correlation between clinical potency and antagonism of the classical dopamine D 2 receptor (Creese et al. 1976; Seeman et al. 1976) . Although recent pharmacological successes have implicated the potential role of several of the newly discovered dopamine receptors (D 3 , D 4 , D 5 ), nondopamine receptors, including serotonergic, adrenergic, and cholinergic receptors, are believed to subserve a specialized function in both the therapeutic action and side effect profiles of antipsychotic drugs (Deutch et al. 1991) .
The mechanism by which neuroleptics induce therapeutic effects remains elusive. Early receptor binding studies demonstrated a strong correlation between clinical potency and antagonism of the classical dopamine D 2 receptor (Creese et al. 1976; Seeman et al. 1976) . Although recent pharmacological successes have implicated the potential role of several of the newly discovered dopamine receptors (D 3 , D 4 , D 5 ), nondopamine receptors, including serotonergic, adrenergic, and cholinergic receptors, are believed to subserve a specialized function in both the therapeutic action and side effect profiles of antipsychotic drugs (Deutch et al. 1991) .
Immediate early genes (IEGs), such as c-fos , can be activated by a variety of physiological and pharmacological stimuli and mediate the synthesis of phosphoprotein Fos Herschman 1989) . Recently, it has been shown that haloperidol, a typical neuroleptic, and clozapine, an atypical antipsychotic, significantly increase neuronal c-fos and related gene expression in a number of forebrain regions (Dragunow et al. 1990; Deutch et al. 1992; Nguyen et al. 1992; Robertson and Fibiger 1992; MacGibbon et al. 1994; Fink-Jensen et al. 1995; Wan et al. 1995) . These studies have indicated that typical and atypical antipsychotic drugs exert regionally distinct effects on neuronal IEG expression in the striatum, lateral septum, and islands of Calleja, although they exhibit quite similar actions on c-fos expression in the nucleus accumbens shell.
In addition to remoxipride, two benzamide derivatives have been introduced as selective antagonists for the dopamine D 2 -like receptor. One is nemonapride, a pyrrolidiny-benzamide derivative (YM-09151-2) (Yamamoto et al. 1982) , which is shown to have high affinity and selectivity for D 2 -like receptors, such as the D 2 , D 3 , and D 4 receptors (Sokoloff et al. 1990; Van Tol et al. 1991; Seeman et al. 1993) . Initial studies have indicated that nemonapride is effective against the positive symptoms and possibly against negative symptoms of schizophrenia (Mori et al. 1989; Satoh et al. 1996) . The second is YM-43611, and this newly developed compound is a D 2 -like receptor antagonist with negligible affinity for other neurotransmitter receptors Ohmori et al. 1996) . Nemonapride has a higher affinity for D 2 receptors than either D 3 or D 4 receptors, whereas YM-43611 exhibits a 5-fold greater selectivity for rat D 3 than D 2 receptors and 90-fold greater selectivity for rat D 4 than D 2 receptors; D 4 selectivity was an order of magnitude greater than that of clozapine .
To understand fully the mechanism of various actions of the neuroleptics, we investigated the acute effects of these benzamides on induction of IEG in the rat forebrain and compared them with those of haloperidol and clozapine. We particularly focused on regions that had been emphasized previously in relation to the drug action (e.g., striatum, lateral septum, nucleus accumbens, and islands of Calleja). The data on IEG induction in the cerebral cortex, diencephalon, and other regions will be dealt with in a different report.
MATERIALS AND METHODS

Drugs
Haloperidol (Dainippon, Osaka) and clozapine (Sandoz, Dorval, Québec) were dissolved in 40 ml of 20% acetic acid and were brought to final volume with distilled water (0.5 ml/kg). YM-43611, (S)-( ϩ )-N-(1-benzyl-3-pyrrolidinyl)-5-chloro-4-cyclopropylcarbonylamino-2-methoxybenzamide (Yamanouchi), and nemonapride (emonapride; YM-09151-2), cis-N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-methyaminobenzamide (Yamanouchi, Tokyo) were dissolved in dilute hydrochloric acid (0.05 M).
Protocol
Male Wistar rats (body weight, 150-200 g) were grouphoused (3 per cage) for 1 week before injections of haloperidol (1 mg/kg, n ϭ 6), clozapine (25 mg/kg, n ϭ 6), YM-43611 (0.1, 1.0, 5.0, 10.0 mg/kg, n ϭ 10), nemonapride (0.5, 4.0 mg/kg, n ϭ 10), or two vehicle solutions ( n ϭ 12). All of the injection solutions, including those for the controls, were matched on the basis of pH. Each animal received a single subcutaneous injection in the left thigh.
Fos Immunohistochemistry
Two hours after vehicle or drug injection, the rats were anesthetized with sodium pentobarbital (50 mg/kg IP) and were perfused with 0.9% saline followed by 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). The brains were removed and placed in the same fixative for 24 hours. Thirty-micrometer-thick sections were cut from each brain with a vibratome. After a rinse in phosphate buffer saline, the sections were incubated with anti-c-Fos polyclonal antibody (Ab2: Oncogene Science, Uniondale, NY; diluted 1:2,000). This antibody has been shown to recognize N-terminal region of c-Fos and related proteins in the rat central nervous system (MacGibbon et al. 1994) . The specificity of the immunoreactivity was examined by an absorption test using synthetic c-Fos peptide (N-terminal 16 amino acid residues; Cambridge Res. Biochem., Wilmington, DE, . No immunoreactivity was observed in these control studies. The reaction products were detected using PK4001 kits (Vector, Burlingame, CA) and finally visualized by the diaminobenzidine-ammonium-nickel method. Some of the sections were counterstained with neutral red for anatomical verification, and the atlas of Paxinos and Watson (1986) was used as a reference.
Statistical Analysis
The number of c-Fos-like immunoreactive (FLI) cells were counted in a unit area (Figure 1 ). The differences between groups in the number of FLI cells were evaluated using one-way analysis of variance (ANOVA, Scheffe's F test) for each brain region (Table 1) .
RESULTS
In comparison with vehicle-injected groups, low doses of YM-43611 (0.1 mg/kg) produced no significant changes in the distribution of FLI cells. Treatments with higher doses of YM-43611 (5, 10 mg/kg) resulted in similar distributions of FLI cells, as will be indicated.
Septum and Other Medial Forebrain Regions
Significant increases in the number of FLI cells were observed in the lateral septal nucleus and diagonal band nucleus after treatment with clozapine ( Figure 2A ), but not with YM-43611, haloperidol, or nemonapride (Table  1) . No significant increases in the number of positive cells were observed in the olfactory tubercle or the bed nucleus of stria terminalis in any of the drug-treated rats. Significant increases in the number of FLI cells were observed in the medial prefrontal cortex after treatment with clozapine and nemonapride, but not with YM-43611 or haloperidol (Table 1) .
Nucleus Accumbens and Island of Calleja
In the nucleus accumbens shell, there were significant increases in the number of FLI cells after the injection of YM-43611 or either of the three antipsychotics ( Figure  2B ; Table 1 ). The distribution was similar for each drug, and the dorsal part of the shell contained relatively more FLI cells than the ventral part. On the other hand, significant increases in the number of positive cells were observed in the nucleus accumbens core after injection of haloperidol or nemonapride, but not after YM-43611 or clozapine (Table 1) .
In the ventromedial basal forebrain, significant increases in the number of FLI cells were observed in the islands of Calleja of YM-43611-, clozapine-, or nemonapride-treated rats, particularly in the major island of Calleja (Figure 3A-3D ; Table 1 ). The FLI cells were distributed heavily in the major island of Calleja. Haloperidol injection slightly enhanced the induction of positive cells in the islands of Calleja. In the counterstained sections of haloperidol-treated animals, the great majority of neurons in the major island of Calleja were not Fos positive.
Striatum
In the striatum of rats treated with either haloperidol or nemonapride, significant increases were observed in the number of FLI cells (Figure 3F and 3G; Table 1 ). YM-43611 injection resulted in a slight increase of FLI cells ( Figure 3H ). In contrast, clozapine had little effect on c-fos expression in the striatum.
DISCUSSION
In the present study, the effect of acute administration of the two benzamides, both selective dopamine D 2 -like receptor antagonists, on IEG expression was investigated in the rat forebrain. The distribution of responding neurons, as reflected by the enhanced induction of Fos-like proteins, after a single injection of YM-43611 or nemonapride was compared with that seen in a typical neuroleptic, haloperidol, as well as an atypical antipsychotic, clozapine. The distributions of Fos-positive cells after haloperidol or clozapine treatment were similar, but not identical, to those previously reported (Dra- Paxinos and Watson (1986) and of Satoh et al. (1983) for anatomical nomenclature. ACS, nucleus accumbens shell; ACC, nucleus accumbens core; CP, caudate putamen; DB, diagonal band nucleus; MS, medial septal nucleus; MiC, major islands of Calleja; mpf, medial prefrontal cortex; LS, lateral septal nucleus; OT, olfactory tubercle; SHy, septohypothalamic nucleus; bst, bed nucleus of stria terminalis. gunow et Deutch et al., 1992; Robertson and Fibiger 1992; Nguyen et al. 1992) .
The forebrain regions that were common to YM-43611, nemonapride, haloperidol, and clozapine with respect to induction of enhanced IEG expression were the nucleus accumbens and, with the exception of haloperidol, the islands of Calleja. However, it was only in the nucleus accumbens shell that all four drugs produced statistically significant increases in the number of FLI cells. The present finding that nemonapride is effective in such IEG induction extends earlier observations in rats (Robertson and Fibiger 1992; Deutch et al. 1992; MacGibbon et al. 1994 ) and monkeys (Ikemoto et al. 1995) and suggests that the nucleus accumbens shell may be a site of antipsychotic action.
A recent receptor binding autoradiographic study revealed one of the highest levels of D 3 binding in the nucleus accumbens (Booze and Wallace 1995) , where the density of D 2 and D 3 receptor subtypes displayed a 1:1 ratio. Nemonapride has a high affinity and selectivity for D 2 like receptors (Terai et al. 1989 ); however, this drug is not selective for either D 3 or D 4 receptors over D 2 receptors . In contrast, YM-43611 exhibits moderate selectivity for D 3 receptors and high selectivity for D 4 receptors. Because both YM-43611 and nemonapride enhanced the induction of c-Fos-like proteins in the nucleus accumbens shell, it is conceivable that dopamine D 3 receptor antagonism, in addition to D 2 receptor antagonism, accounts for such an increase in IEG expression following drug administration. Previously, Robertson and Fibiger (1992) demonstrated that 6-OHDA lesions of the mesotelencephalic dopamine system block haloperidol-and clozapine-induced c-fos expression in the nucleus accumbens. Furthermore, Guo et al. (1995) have reported that pretreatment with 7OH-DPAT, a dopamine D 3 receptor agonist, reduces clozapine-induced c-fos expression in the nucleus accumbens shell. In situ hybridization histochemistry has revealed high levels of dopamine D 2 and D 3 receptor mRNA in the nucleus accumbens shell (Sokoloff et al. 1990; Mansour et al. 1990; Bouthenet et al. 1991; Diaz et al. 1995) . MacGibbon and colleagues (1994) demonstrated strong IEG (FRA, not c-Fos) induction in the islands of Calleja after clozapine treatment, but not after haloperidol injection. Guo et al. (1995) demonstrated that 7-OH-DPAT pretreatment significantly attenuated the clozapine-induced increase in the major island of Calleja. The present study confirmed these findings and further demonstrated that the two benzamides YM-43611 and nemonapride significantly increase the number of FLI cells in the major island of Calleja. Haloperidol did not result in a significant increase of FLI cells in the major island of Calleja, although an increasing trend was observed. This dissimilarity between drugs likely originates from the difference in the pharmacological characteristics of these antipsychotic drugs. YM-43611, nemonapride, and clozapine, but not haloperidol, exhibit high affinity for dopamine D 3 and/or D 4 receptors (Sokoloff et al. 1990; Bouthenet et al. 1991; Van Tol et al. 1991) . One of the highest levels of D 3 receptor binding was observed in the islands of Calleja (Hillefors-Berglund and VonEuler 1994; Booze and Wallace 1995) . In situ hybridization histochemical studies have shown that the islands of Calleja exhibit high dopamine D 3 receptor mRNA messages in the rat (Sokoloff et al. 1990; Bouthenet et al. 1991; Diaz et al. 1995) . A remarkable difference between the two benzamides in terms of IEG induction occurred in the striatum. Like haloperidol, nemonapride markedly enhanced the number of FLI neurons in the striatum, but YM-43611 at the present doses did not. This differential induction could be brought about by different profiles in D 2 receptor blockade, as the striatum has high concentrations of D 2 receptors (Booze and Wallace 1995) . In contrast to nemonapride, YM-43611 is a D 2 -like receptor antagonist with a 5-fold lower affinity for rat D 2 than D 3 receptors; such a pharmacological characteristic may account for failure to enhance intense striatal IEG expression. Similarly, an increase in Fos immunoreactivity was observed in the nucleus accumbens core following nemonapride and haloperidol administration, but not after YM-43611 or clozapine treatment.
In the septum, haloperidol and clozapine produced significant increases of FLI-positive cells in the septohypothalamic nucleus, but clozapine alone induced a significant increase of FLI cells in the lateral septum. Previous studies (Robertson and Fibiger 1992; MacGibbon et al. 1994) have shown that the number of FLI neurons in the lateral septal nucleus (ventral part) are increased by haloperidol as well as clozapine (higher c-Fos induction by clozapine than haloperidol), although data on the adjacent septohypothalamic nucleus were not presented. The reason for the discrepancy between the present and previous studies is not clear. It may arise from a difference in the antibody used. Moreover, as the distribution pattern of FLI cells was uneven in the lateral septal area (including the septohypothalamic nucleus), the discrepancy might merely be a sampling effect (different region of interest).
The present results are in accord with previous observations (Robertson and Fibiger 1992; MacGibbon et al. 1994 ) that clozapine enhances IEG expression in the ventral septum. Unlike clozapine, the two benzamides failed to affect IEG expression in the lateral septal area. The reason for this difference is uncertain. Although clozapine has antagonist effects on D 2 -like receptors, it also has effects on other receptors, such as serotonergic (Canton et al. 1990 ), cholinergic, and adrenergic receptors (Tamminga and Gerlach 1987; Baldessarini et al. 1992) . These antagonist properties of clozapine on nondopaminergic receptors might result in enhancing IEG expression in the lateral septum.
In the medial prefrontal cortex, clozapine and nemonapride produced significant increases in the number of FLI cells, whereas YM-43611 and haloperidol did not. Guo et al. (1995) demonstrated that pretreatment with 7-OH-DPAT, a D 3 agonist, did not significantly decrease clozapine-induced IEG expression in the medial prefrontal cortex and raised the possibility that the primary mechanism by which clozapine increases IEG expression in the prefrontal cortex might be due to antagonist actions at D 4 receptors. However, a recent pharmacological study argued against simple D 3 or D 4 antagonism as the cause of such changes in IEG expres- sion in the medial prefrontal cortex (Deutch and Duman 1996) , as many D 2 -like receptor antagonists do not change c-fos expression in this region. The present study, taken together with previous reports, suggest that simple D 2 -like receptor antagonism is not sufficient to induce IEG expression in the medial prefrontal cortex.
CONCLUSION
YM-43611 treatment enhanced c-Fos immunoreactivity in selective regions of the rat forebrain. As YM-43611 produced an increase in the number of FLI cells in the nucleus accumbens shell and islands of Calleja, as some other antipsychotics did, it is hypothesized that this benzamide has potential as an antipsychotic drug. YM-43611 shows a moderate selectivity for the dopamine D 3 receptor (K i 35.5 nM) and a high selectivity for D 4 receptor (K i 1.85 nM) . Although antagonist actions at D 3 receptors may account for the ability of YM-43611 to increase FLI in the nucleus accumbens shell and the islands of Calleja, the extent to which D 4 blockade contributed to the present IEG results is not clear. D 4 receptor mRNA is localized more abundantly in the cerebral cortex, hypothalamus, and amygdala than in the regions studied here (O'Malley et al. 1992 ). The present study points to the need for future studies using highly selective D 4 receptor antagonists.
